Jennifer Pietenpol Archive
-
December 15, 2023
Clinical trial shows efficacy for atezolizumab combined with carboplatin
-
March 22, 2022
VUMC’s Pietenpol, Shyr named AACR Fellows
Vanderbilt's Jennifer Pietenpol, PhD, and Yu Shyr, PhD, have been inducted as fellows of the American Association for Cancer Research Academy. -
February 17, 2022
Park named director of Vanderbilt-Ingram Cancer Center
Ben Ho Park, MD, PhD, deputy director of the Vanderbilt-Ingram Cancer Center, has been named the center’s new director. -
February 10, 2022
Pietenpol named chief scientific and strategy officer
Jennifer Pietenpol, PhD, director of the Vanderbilt-Ingram Cancer Center (VICC), Benjamin F. Byrd Jr. Professor of Oncology and Executive Vice President for Research for Vanderbilt University Medical Center, is stepping down on June 30 from her long-held role as the Cancer Center’s director to focus on a combined leadership role for VUMC as chief scientific and strategy officer (CSSO). -
November 18, 2021
‘Multi-omics’ reveals treatment option for breast cancer subtype
-
September 2, 2021
Discovery offers insight for development of cancer therapies targeting mutant p53
Vanderbilt researchers have discovered that aneuploidy (an abnormal number of chromosomes) drives malignant phenotypes in cells expressing mutant p53, a tumor suppressor protein that is mutated in more than half of all human cancers. -
August 19, 2021
Expression atlas for cell regulators
Vanderbilt researchers report a comprehensive tissue-specific atlas of protein and mRNA expression for p63 and p73, members of the p53 family signaling network that is the most frequent target of mutations in human cancers.